CompletedNCT00721955
Inhaled loxapine or placebo for acute agitation in bipolarity type I
About this title
Staccato Loxapine in Agitated Patients With Bipolar Disorder
Read the official source — NCT00721955Researchers compared Inhaled loxapine 5 mg, Inhaled loxapine 10 mg and placebo to find out how the approaches affected psychotic symptoms in people with bipolarity type I.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared Inhaled loxapine 5 mg, Inhaled loxapine 10 mg and placebo to find out how the approaches affected psychotic symptoms in people with bipolarity type I.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Escondido and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 314
- Sponsor
- Alexza Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00721955
- Official title
Show the full official title
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Escondido · Garden Grove · Atlanta
3 more locations
- Austin
- Houston
- Bellevue
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Inhaled loxapine 5 mg, Inhaled loxapine 10 mg and placebo to find out how the approaches affected psychotic symptoms in people with bipolarity type I.
Who is behind this study?
The study sponsor is Alexza Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including Inhaled Placebo, Inhaled loxapine 5 mg and Inhaled loxapine 10 mg.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
